Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

EndocrineGastrointestinalThoracic

Lung Neoplasms

NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Phase 1/2 Terminated

13 enrolled

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07398937 2026-02-10

ECTOP-1036

116 enrolled

Lung Neoplasms

NCT05234307 2026-02-06

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Recruiting

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07394062 2026-02-06

ALCG-01

Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts

Phase 1 Active not recruiting

Lung Neoplasms

NCT03025256 2026-01-08

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

71 enrolled

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Phase 3 Active not recruiting

55 enrolled

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03391869 2025-12-17

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

339 enrolled

Phase 1 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05681780 2025-12-04

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

13 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

51 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04991025 2025-10-20

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

60 enrolled

Lung Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

1 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06926790 2025-04-22

GALAXY 3

69 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06495125 2025-04-17

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

50 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT05012254 2025-04-09

NIVIPI-Brain

71 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02664181 2024-09-03

PRECISE

13 enrolled 14 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06572722 2024-08-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

200 enrolled

Lung Neoplasms

NCT04300244 2024-02-29

NIPU

Other solid neoplasmThoracic

118 enrolled

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma, Neoplasms

NCT05041062 2024-01-03

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Other solid neoplasmThoracic

2 enrolled 8 charts

Lung Neoplasms, Mesothelioma

NCT05081674 2023-10-11

BLISS

154 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02831933 2023-09-21

ENSIGN

11 enrolled 9 charts

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03662074 2023-08-02

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

14 enrolled 14 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03313544 2023-04-21

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Phase 4 Unknown

50 enrolled

Lung Neoplasms, Melanoma

NCT03406715 2023-03-30

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

14 enrolled 12 charts

DermatologicGenitourinaryThoracic

Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03041181 2022-07-11

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

3 enrolled 11 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT04173325 2022-06-14

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Phase 1 Terminated

10 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02768558 2021-06-02

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

Phase 3 Terminated

20 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Phase 1/2 Terminated

1 enrolled 12 charts

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT03256136 2020-11-04

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

9 enrolled 15 charts

GastrointestinalGenitourinaryHead & NeckThoracic

Lung Neoplasms

NCT02946671 2020-03-06

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Phase 1 Completed

16 enrolled

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mouth Neoplasms, Stomach Neoplasms

NCT02469701 2020-02-17

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

10 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Phase 1/2 Withdrawn